MB
EVMN

MPM BioImpact’s Evommune Inc EVMN Stock Holding History

MPM BioImpact’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,455,863
Closed -$33.5M – 48
2026
Q1 		$33.5M Buy
1,455,863
+1,342,841
+1,188% +$30.4M 2.58% 15
2025
Q4 		$1.93M Buy
+113,022
New +$2.12M 0.22% 36

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

MPM BioImpact's EVMN Position: Q2 2026 in Review

MPM BioImpact sold out of Evommune Inc (EVMN) in Q2 2026, closing a stake of 1,455,863 shares — an estimated $33.5M sold.

MPM BioImpact first reported a position in EVMN in Q4 2025 and held it in 2 quarters. The position peaked at $33.5M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • MPM BioImpact reported no remaining Evommune Inc position as of Q2 2026 after selling out during the quarter.
  • MPM BioImpact sold 1,455,863 Evommune Inc shares in Q2 2026, an estimated $33.5M.
  • MPM BioImpact first reported a position in Evommune Inc in Q4 2025 and held it in 2 quarters.
  • MPM BioImpact's Evommune Inc position peaked at $33.5M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.